cladribine has been researched along with Chemotherapy-Induced Febrile Neutropenia in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aviv, A; Bairey, O; Braester, A; Dally, N; Fineman, R; Goldschmidt, N; Greenbaum, U; Herishanu, Y; Inbar, M; Levy, I; Polliack, A; Rouvio, O; Ruchlemer, R; Shaulov, A; Shvidel, L; Tadmor, T; Yuklea, M | 1 |
1 other study(ies) available for cladribine and Chemotherapy-Induced Febrile Neutropenia
| Article | Year |
|---|---|
Primary peg-filgrastim prophylaxis versus filgrastim given "on demand" for neutropenia during therapy with cladribine for hairy cell leukemia.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Chemotherapy-Induced Febrile Neutropenia; Cladribine; Female; Filgrastim; Humans; Israel; Length of Stay; Leukemia, Hairy Cell; Leukocyte Count; Male; Middle Aged; Neutrophils; Polyethylene Glycols; Pre-Exposure Prophylaxis; Retrospective Studies; Survival Analysis; Treatment Outcome | 2019 |